In recent years, there has been increasing interest in the development of medical decision-support tools, including dashboard systems. Dashboard systems are software packages that integrate information and calculations about therapeutics from multiple components into a single interface for use in the clinical environment. Given the high cost of medical care, and the increasing need to demonstrate positive clinical outcomes for reimbursement, dashboard systems may become an important tool for improving patient outcome, improving clinical efficiency and containing healthcare costs. Similarly the costs associated with drug development are also rising. The use of model-based drug development (MBDD) has been proposed as a tool to streamline this...
Biological medicinal products (BMPs) are a successful class of drugs that are indicated in numerous ...
Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstra...
AbstractRecent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Adm...
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Multiple software programs are available for designing and running large scale system-level pharmaco...
The development of a new drug is an extremely high-risk enterprise. The attrition rates of developme...
The idea of model-based drug development championed by Lewis Sheiner, in which pharma-costatistical ...
Modeling and simulation are becoming indispensable elements in drug development. Mechanistic modelin...
Model‐informed drug development (MIDD) is a process intended to expedite drug development, enhance r...
The healthcare system is experiencing a paradigm shift in delivering its services, evolving from a r...
This book offers a high-level treatise of evidence-based decisions in drug development. Because of t...
This study evaluates whether an adaptive development and licensing approach to drug development, com...
The development of essential medicines is being slowed by a lack of efficiency in drug development a...
AbstractModels for assessing health and economic outcomes of new drugs have an increasing role in th...
OBJECTIVE: To describe the development, as part of the European Union MOSAIC (Models and Simulation...
Biological medicinal products (BMPs) are a successful class of drugs that are indicated in numerous ...
Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstra...
AbstractRecent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Adm...
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Multiple software programs are available for designing and running large scale system-level pharmaco...
The development of a new drug is an extremely high-risk enterprise. The attrition rates of developme...
The idea of model-based drug development championed by Lewis Sheiner, in which pharma-costatistical ...
Modeling and simulation are becoming indispensable elements in drug development. Mechanistic modelin...
Model‐informed drug development (MIDD) is a process intended to expedite drug development, enhance r...
The healthcare system is experiencing a paradigm shift in delivering its services, evolving from a r...
This book offers a high-level treatise of evidence-based decisions in drug development. Because of t...
This study evaluates whether an adaptive development and licensing approach to drug development, com...
The development of essential medicines is being slowed by a lack of efficiency in drug development a...
AbstractModels for assessing health and economic outcomes of new drugs have an increasing role in th...
OBJECTIVE: To describe the development, as part of the European Union MOSAIC (Models and Simulation...
Biological medicinal products (BMPs) are a successful class of drugs that are indicated in numerous ...
Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstra...
AbstractRecent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Adm...